84057-95-4
84057-95-4
Chemical Structure
Ropivacaine
- CAS No.: 84057-95-4
- Formula:C17H26N2O
- Molecular Weight:274.40
IUPAC Name: (S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
InChIKey: ZKMNUMMKYBVTFN-HNNXBMFYSA-N
SMILES: O=C([C@H]1N(CCC)CCCC1)NC2=C(C)C=CC=C2C
Biological Activity: Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ropivacaine | 99.98% | Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of neuropathic pain management. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ropivacaine (Standard) | ≥98% | Ropivacaine (Standard) is the analytical standard of Ropivacaine. This product is intended for research and analytical applications. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of neuropathic pain management. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ropivacaine-d7 | 99.69% | Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent?sodium channel?blocker. Ropivacain blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is used for the research of neuropathic pain?management. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ropivacaine-d7 hydrochloride | Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B). Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine is widely used for neuropathic pain management in vivo. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Ropivacaine-d7 | (Rac)-Ropivacaine-d7 is the deuterium labeled (Rac)-Ropivacaine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.98
HY-B0563BRopivacaine hydrochloride -
Similarity Score 0.98
HY-W099429Ropivacaine impurity 1 hydrochloride -
Similarity Score 0.97
HY-B0563ARopivacaine hydrochloride monohydrate -
Similarity Score 0.94
HY-B0405Bupivacaine -
Similarity Score 0.94
HY-B0653Levobupivacaine -
Similarity Score 0.93
HY-B0405ARBupivacaine hydrochloride (Standard) -
Similarity Score 0.93
HY-Z6848(R)-(+)-Bupivacaine hydrochloride -
Similarity Score 0.92
HY-B0405SBupivacaine-d9 -
Similarity Score 0.92
HY-W415121Bupivacaine hydrochloride monohydrate -
Explore the MedChemAI to find more analogs
References
- [1]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717. [Content Brief]
- [2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321. [Content Brief]
- [3]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth [Content Brief]
